



10 NOVEMBER 2020

LITTLE GREEN PHARMA ENTERS STRATEGIC PARTNERSHIP WITH HIF ASX ANNOUNCEMENT

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to announce it has entered into a strategic partnership with national private health insurer Health Insurance Fund of Australia (“HIF”).

The partnership with HIF will support improved access to and affordability of medicinal cannabis products through the payment of a rebate to eligible HIF members.

The partnership also encompasses future research to advance the understanding of the role medicinal cannabis can play in improving patient quality of life, with eligible HIF members entitled to priority participation in such research. The term of the partnership is for between 18 months and 2 years depending on the length of the study. The consideration payable by HIF is not material to the Company and all conditions precedent have been satisfied.

Fleta Solomon, Managing Director of LGP said the partnership is an exciting development for both HIF members and LGP:

“Our company has always had Australian patient access at the forefront. We were the first company in Australia to launch with locally-grown and affordable medicinal cannabis products. Our disruptive pricing strategy led to the cost of medicinal cannabis products being significantly reduced in price nationally. We are proud to further contribute to driving improved affordability and our partnership with HIF, another patient-focused company, will mean better access to medicinal cannabis products for patients across Australia.”

A copy of the HIF media release, which provides further details of the partnership, is attached.





ENDS

BY ORDER OF THE BOARD

A handwritten signature in dark ink, appearing to read "Alistair Warren", written over a horizontal line.

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: alistair@lgpharma.com.au
M: +61 8 6280 0050

Fleta Solomon
Managing Director
Little Green Pharma
E: fleta@lgpharma.com.au
M: +41 782 260 200



About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

Media Release
10 November 2020

**HIF, LITTLE GREEN PHARMA ENTER PARTNERSHIP IN SUPPORT OF MEDICINAL
CANNABIS ACCESS AND RESEARCH IN AUSTRALIA**

National private health insurer Health Insurance Fund of Australia (HIF) has formed a strategic partnership with Australian medicinal cannabis manufacturer Little Green Pharma (LGP) to support improved access and research into medicinal cannabis as a treatment option for Australian patients.

The partnership with West Australian-based LGP reflects increasing community interest and scientific evidence supporting medicinal cannabis as a significant treatment for many Australian patients.

It also represents the first time a major Australian health fund has publicly declared its support for access to medicinal cannabis treatments and the potential benefits it can have on the lives of Australians who are suffering from numerous debilitating health conditions.

A proudly Australian business, LGP produces an affordable range of high quality, strictly-tested CBD, balanced and THC-dominant medical cannabis oil products locally manufactured in Western Australia and available to Australian patients nationally via doctor prescription.

What does this mean for HIF members?

HIF will pay rebates for medicinal cannabis across all but one of its Extras policies with eligible members receiving up to \$105 back per script¹.

HIF and LGP will also be partnering to support future research to advance the understanding of the role medicinal cannabis can play in improving patient quality of life, with eligible HIF members entitled to priority participation in such research.

Justin James, CEO of HIF, said supporting medicinal cannabis and partnering with Little Green Pharma was well aligned with HIF's goals of providing new, alternative treatment choices to its members.

"We are exceptionally pleased to be the first Australian health fund to publicly declare our support for medicinal cannabis treatments and provide our members with rebates on these products.

"As a member-based health fund, our community is the motivation for everything we do, so assisting members through treatment options that can dramatically improve quality of life across different life stages is a key focus.

¹ Rebates subject to individual policy caps

“HIF proudly provides choice to members – whether of specialist, hospital, clinic or medication – so our members can have the flexibility to control their own medical outcomes. Supporting members with medical cannabis as a treatment option is another choice, we are excited to provide to members.”

Mr James said HIF was also proud to support research into the potential benefits of medicinal cannabis, something both HIF and LGP were keen to pursue as soon as possible.

“Global research is showing promise, so we look forward to supporting more research being undertaken on local soil,” he added.

Fleta Solomon, Managing Director of LGP said the partnership is an exciting development for both HIF members and LGP.

“Our company has always had Australian patient access at the forefront. We were the first company in Australia to launch with locally grown and affordable medicinal cannabis products. Our disruptive pricing strategy led to the cost of medicinal cannabis products being significantly reduced in price nationally. We are proud to further contribute to driving improved affordability and our partnership with HIF, another patient-focused company, will mean better access to medicinal cannabis products for patients across Australia.”

For further information for HIF members, visit: <https://www.hif.com.au/help/claiming-information/medicinal-cannabis-and-treatment-access>

ENDS

For media enquiries/ interview requests:

HIF

Jodie Carlson
Communications Manager, HIF
Jodie.carlson@hif.com.au
0409 244 365

Little Green Pharma

David Tasker
Chapter One Advisors
dtasker@chapteroneadvisors.com.au
0433 112 936



About HIF

HIF has been supporting its members and their families' health and wellbeing for over 65 years. A not-for-profit health fund, HIF provides choice to its members. Whether it's choice of hospital, specialist, or other provider, we give members total freedom to make these decisions when it comes to their health.

For more information about HIF go to <https://www.hif.com.au/>

About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution. The Company has an indoor cultivation and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to over 6,700 patients in Australia and overseas.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com